Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2021 16:00 ET | Source: PAVmed Inc.

PAVmed Provides Business Update and First Quarter 2021 Financial Results

Conference call to be held today at 4:30 PM EDT NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product,...
May 06, 2021 09:30 ET | Source: PAVmed Inc.

PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team

Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ)...
February 22, 2021 08:18 ET | Source: PAVmed Inc.

PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results

Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its...
November 17, 2020 16:00 ET | Source: PAVmed Inc.

PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update

Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
February 20, 2020 09:30 ET | Source: PAVmed Inc.

PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™

Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer...
February 11, 2020 09:30 ET | Source: PAVmed Inc.

U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...